The Association for the British Pharmaceutical Industry (ABPI) Code of Practice defines a Grant as funds, that are freely given for the purpose of supporting healthcare, scientific research, or education, with no consequent obligation on the recipient organisation to provide goods or services to the benefit of the pharmaceutical company in return.
Grants must not:
- constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific medicines.
- be provided retrospectively.
- be provided to individuals.
- bear the name of any medicine.
- offset any normal operating expense.
Examples of what cannot be submitted via the Grant application process:
- Support in the form of a financial contribution for
individuals to:
- attend meetings/events
- undertake Research Fellowships
- Clinical research associated with Novo Nordisk products, including Investigator Sponsored Studies
- Sponsorship of scientific meetings, events, or congresses
- Collaborative Working projects
2025 application window is now closed.
All applications submitted up to 31 March 2025 will be reviewed by the Novo Nordisk Grant Panel and applicants will be informed of the Panel decision by end of May 2025.
Novo Nordisk reserves the right to open a second application window should funding allow – this would likely occur in the second half of the year.
A contract will be put in place between Novo Nordisk and the recipient organisation. The contract, amongst other things, will require the recipient organisation to:
- Issue an invoice to Novo Nordisk for the Grant for payment to be made.
- Provide Novo Nordisk with confirmation that the Grant was used for the intended purpose at the end of the grant term.
- Display a clear and prominent declaration on any materials created as a result of the Grant, which accurately outlines Novo Nordisk’s funding.
All Grants will be publicly disclosed in accordance with ABPI Code of Practice requirements. See Disclosure UK for further details: About Disclosure UK (abpi.org.uk).